These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

632 related items for PubMed ID: 15050096

  • 1. C-reactive protein is not only an inflammatory marker but also a direct cause of cardiovascular diseases.
    Li JJ, Fang CH.
    Med Hypotheses; 2004; 62(4):499-506. PubMed ID: 15050096
    [Abstract] [Full Text] [Related]

  • 2. Persistent activation of nuclear factor kappa-B signaling pathway in patients with unstable angina and elevated levels of C-reactive protein evidence for a direct proinflammatory effect of azide and lipopolysaccharide-free C-reactive protein on human monocytes via nuclear factor kappa-B activation.
    Liuzzo G, Santamaria M, Biasucci LM, Narducci M, Colafrancesco V, Porto A, Brugaletta S, Pinnelli M, Rizzello V, Maseri A, Crea F.
    J Am Coll Cardiol; 2007 Jan 16; 49(2):185-94. PubMed ID: 17222729
    [Abstract] [Full Text] [Related]

  • 3. [Inflammatory markers and cytokines in cardiovascular disease].
    Ogiwara F, Takahashi M, Ikeda U.
    Rinsho Byori; 2004 Aug 16; 52(8):686-92. PubMed ID: 15478624
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Inflammatory mechanisms in atherosclerosis: from laboratory evidence to clinical application.
    Blake GJ, Ridker PM.
    Ital Heart J; 2001 Nov 16; 2(11):796-800. PubMed ID: 11770860
    [Abstract] [Full Text] [Related]

  • 6. Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
    Ray KK, Cannon CP, Cairns R, Morrow DA, Rifai N, Kirtane AJ, McCabe CH, Skene AM, Gibson CM, Ridker PM, Braunwald E, PROVE IT-TIMI 22 Investigators.
    J Am Coll Cardiol; 2005 Oct 18; 46(8):1417-24. PubMed ID: 16226164
    [Abstract] [Full Text] [Related]

  • 7. High-dose statin and COX-2 inhibitor therapy rapidly decreases C-reactive protein level in patients with unstable angina.
    Chyrchel M, Dudek D, Bartuś S, Legutko J, Heba G, Dubiel JS.
    Kardiol Pol; 2004 Sep 18; 61(9):213-21; discussion 222-4. PubMed ID: 15531933
    [Abstract] [Full Text] [Related]

  • 8. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study.
    Hanefeld M, Marx N, Pfützner A, Baurecht W, Lübben G, Karagiannis E, Stier U, Forst T.
    J Am Coll Cardiol; 2007 Jan 23; 49(3):290-7. PubMed ID: 17239709
    [Abstract] [Full Text] [Related]

  • 9. C-reactive protein. Should it be considered a coronary risk factor?
    Aronow WS.
    Geriatrics; 2003 May 23; 58(5):19-22, 25. PubMed ID: 12756677
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. [C-reactive protein in cardiovascular risk evaluation].
    Fabijanić D, Banić M, Kardum D.
    Lijec Vjesn; 2006 May 23; 128(5-6):167-74. PubMed ID: 16910418
    [Abstract] [Full Text] [Related]

  • 13. Effect of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on high-sensitivity C-reactive protein levels.
    Field KM.
    Pharmacotherapy; 2005 Oct 23; 25(10):1365-77. PubMed ID: 16185181
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Statins reduce interleukin-6-induced C-reactive protein in human hepatocytes: new evidence for direct antiinflammatory effects of statins.
    Arnaud C, Burger F, Steffens S, Veillard NR, Nguyen TH, Trono D, Mach F.
    Arterioscler Thromb Vasc Biol; 2005 Jun 23; 25(6):1231-6. PubMed ID: 15790934
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular disease: C-reactive protein and the inflammatory disease paradigm: HMG-CoA reductase inhibitors, alpha-tocopherol, red yeast rice, and olive oil polyphenols. A review of the literature.
    Patrick L, Uzick M.
    Altern Med Rev; 2001 Jun 23; 6(3):248-71. PubMed ID: 11410071
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. From pathophysiology to targeted therapy for atherothrombosis: a role for the combination of statin and aspirin in secondary prevention.
    Chapman MJ.
    Pharmacol Ther; 2007 Jan 23; 113(1):184-96. PubMed ID: 17070923
    [Abstract] [Full Text] [Related]

  • 20. Changes of plasma inflammatory markers after withdrawal of statin therapy in patients with hyperlipidemia.
    Li JJ, Li YS, Chu JM, Zhang CY, Wang Y, Huang Y, Chen J, Yuan JQ, Huang YL.
    Clin Chim Acta; 2006 Apr 23; 366(1-2):269-73. PubMed ID: 16343471
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.